Alison Bateman-House

1.0k total citations
46 papers, 496 citations indexed

About

Alison Bateman-House is a scholar working on Physiology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Alison Bateman-House has authored 46 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Physiology, 17 papers in Public Health, Environmental and Occupational Health and 15 papers in Economics and Econometrics. Recurrent topics in Alison Bateman-House's work include Biomedical Ethics and Regulation (31 papers), Ethics in Clinical Research (13 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). Alison Bateman-House is often cited by papers focused on Biomedical Ethics and Regulation (31 papers), Ethics in Clinical Research (13 papers) and Health Systems, Economic Evaluations, Quality of Life (13 papers). Alison Bateman-House collaborates with scholars based in United States, United Kingdom and Germany. Alison Bateman-House's co-authors include Arthur L. Caplan, Laura L. Kimberly, Christopher T. Robertson, Holly Fernandez Lynch, Barbara K. Redman, Brendan Parent, Gwendolyn P. Quinn, Aron Janssen, Michael Shen and Lea Ann Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and Nature Biotechnology.

In The Last Decade

Alison Bateman-House

41 papers receiving 473 citations

Peers

Alison Bateman-House

PHYSI

PHEOH

Brendan Parent United States

Rachel Horton United Kingdom

Alison Stewart United Kingdom

Íñigo de Miguel Beriaín Spain

Tereza Hendl Germany

Eva Rodríguez Spain

Lisa Judy Chin United States

Ebtesam Esmail Hassan Egypt

Catherine Wicklund United States

Catherine Laporte France

Brendan Parent United States

Alison Bateman-House

44 ×0.2

PHYSI

293 ×2.0

PHEOH

115 ×0.8

12 ×0.1

78 ×1.3

Citations per year, relative to Alison Bateman-House Alison Bateman-House (= 1×) peers Brendan Parent

Countries citing papers authored by Alison Bateman-House

Since Specialization

Citations

This map shows the geographic impact of Alison Bateman-House's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Bateman-House with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Bateman-House more than expected).

Fields of papers citing papers by Alison Bateman-House

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Bateman-House. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Bateman-House. The network helps show where Alison Bateman-House may publish in the future.

Co-authorship network of co-authors of Alison Bateman-House

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Bateman-House. A scholar is included among the top collaborators of Alison Bateman-House based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Bateman-House. Alison Bateman-House is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jonker, Anneliene Hechtelt, David Dimmock, Alison Bateman-House, et al.. (2025). From roadmap to a sustainable end-to-end individualized therapy pathway. PubMed. 6. 941248964–941248964. 1 indexed citations

Bateman-House, Alison, et al.. (2024). Lived Experience of Patients and Caregivers in Rare Genetic Neurological Gene Therapy Clinical Trials in Children. Pediatric Neurology. 163. 46–49.

Jonker, Anneliene Hechtelt, Holm Graeßner, David Dimmock, et al.. (2024). The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nature Reviews Drug Discovery. 24(1). 40–56. 10 indexed citations

Cope, Heidi, Emma Heslop, Alexandra Johnson, et al.. (2024). Clinician Perspectives of Gene Therapy as a Treatment Option for Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 11(5). 1085–1093.

Lynch, Holly Fernandez, et al.. (2023). Navigating the Expanded Access Pathway to Investigational Drugs as an Academic Oncologist. JAMA Network Open. 6(2). e230060–e230060.

Kimberly, Laura L., et al.. (2023). The Lived Experience of Pediatric Gene Therapy: A Scoping Review. Human Gene Therapy. 34(23-24). 1180–1189. 6 indexed citations

Bateman-House, Alison, et al.. (2022). Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials. Pharmaceutical Medicine. 37(1). 17–24. 5 indexed citations

Bateman-House, Alison & Lisa S. Kearns. (2021). Investigational Medical Products for Rare Diseases: Ethical Concerns and Unresolved Issues with Expanded Access. 8(S2). 18–23. 1 indexed citations

Bateman-House, Alison, et al.. (2021). Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses. Nucleic Acid Therapeutics. 32(2). 111–117. 11 indexed citations

10.

Caplan, Arthur L., et al.. (2021). Gene therapy companies have an ethical obligation to develop expanded access policies. Molecular Therapy. 29(4). 1367–1369. 13 indexed citations

11.

Bateman-House, Alison, et al.. (2020). Paying for Unapproved Medical Products. Journal of law and policy. 11(1). 85. 5 indexed citations

12.

Grigoryan, Zoya, et al.. (2020). Fecal microbiota transplantation: Uses, questions, and ethics. SHILAP Revista de lepidopterología. 6. 100027–100027. 34 indexed citations

13.

Lynch, Holly Fernandez & Alison Bateman-House. (2020). Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways. The Journal of Law Medicine & Ethics. 48(2). 365–372. 18 indexed citations

14.

Lynch, Holly Fernandez, et al.. (2019). Academic Advocacy: Opportunities to Influence Health and Science Policy Under U.S. Lobbying Law. Academic Medicine. 95(1). 44–51. 6 indexed citations

15.

Kearns, Lisa S., et al.. (2019). What compassionate use means for gene therapies. Nature Biotechnology. 37(4). 352–355. 15 indexed citations

16.

Bateman-House, Alison, et al.. (2018). Improving Expanded Access in the United States: The Role of the Institutional Review Board. Therapeutic Innovation & Regulatory Science. 52(3). 285–293. 8 indexed citations

17.

Caplan, Arthur L., et al.. (2018). A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC). Therapeutic Innovation & Regulatory Science. 53(2). 243–248. 8 indexed citations

18.

Kimberly, Laura L., et al.. (2017). Pre-approval Access Terminology: A Cause for Confusion and a Danger to Patients. Therapeutic Innovation & Regulatory Science. 51(4). 494–500. 17 indexed citations

19.

Bateman-House, Alison, et al.. (2017). Who Stands to Benefit? Right to Try Law Provisions and Implications. Therapeutic Innovation & Regulatory Science. 51(2). 170–176. 6 indexed citations

20.

Dawson, Liza, Alison Bateman-House, Hilary Bok, et al.. (2003). Safety issues in cell-based intervention trials. Fertility and Sterility. 80(5). 1077–1085. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact